Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer

被引：0
|
作者：
Van Raemdonck, E.
Berteloot, P.
Laenen, A.
Han, S.
Van Nieuwenhuysen, E.
Salihi, R.
Concin, N.
Vergote, I.
Floris, G.
Wildiers, H.
Punie, K.
Neven, P.
机构：
[1] KU Leuven Univ Leuven, Leuven, Belgium
[2] KU Leuven Univ Leuven, Lab Translat Cell & Tissue Res, Leuven, Belgium
[3] Univ Leuven, Dept Pathol, Leuven, Belgium
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD3-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-09
引用
收藏
页数：2
相关论文
共 50 条
  • [41] HER2 status in bilateral breast cancer
    Crowe, Joseph P.
    Patrick, Rebecca J.
    Rybicki, Lisa A.
    Budd, G. Thomas
    Escobar, Pedro F.
    Tubbs, Raymond R.
    Hicks, David G.
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2006, 51 (05) : 219 - 223
  • [42] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
  • [43] Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?
    Rodriguez Garces, Maria Yeray
    Fernandez Madrigal, Laura
    Morales Pancorbo, David
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
  • [46] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
  • [47] HER2 Expression in Breast Cancer: Correlation with Endocrine Function and Psychological Status in Operable and Metastatic Breast Cancer
    Lissoni, Paolo
    Messina, Giuseppina
    Rovelli, Franco
    Brivio, Fernando
    Fumagalli, Luca
    Villa, Silvia
    Bartolacelli, Erio
    IN VIVO, 2009, 23 (06): : 987 - 989
  • [48] HER2 STATUS IN PRIMARY AND CORRESPONDING METASTATIC SITES OF GASTRIC CANCER
    Negri, Francesca V.
    Bozzetti, Cecilia
    Lagrasta, Costanza A.
    Crafa, Pellegrino
    Bassano, Cristina
    Tamagnini, Ione
    Gardini, Giorgio
    Nizzoli, Rita
    Leonardi, Francesco
    Gasparro, Donatello
    Camisa, Roberta
    Capelli, Stefano
    Silini, Enrico M.
    Ardizzoni, Andrea
    ANNALS OF ONCOLOGY, 2011, 22 : v19 - v19
  • [49] Variations at HER2 and hormone receptor status in primary and metastatic sites of breast cancer patients.
    Alhan, Nurcan
    Rahatli, Samed
    Kucukoztas, Nadire
    Yalcin, Selim
    Yagmurdur, Mahmut Can
    Dizdar, Omer
    Atilgan, Alev
    Ozdemir, Handan
    Altundag, Ozden
    Ozyilkan, Ozgur
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer
    Janni, W.
    Schramm, A.
    Friedl, T. W. P.
    Schochter, E.
    Huober, J.
    Rack, B.
    Alunni-Fabbroni, M.
    Fasching, P. A.
    Taran, F-A.
    Hortkopf, A.
    Schneeweiss, A.
    Mueller, V.
    Aktas, B.
    Krawczyk, N.
    Pantel, K.
    Fehm, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 47 - 47
12345